Neuronetics Inc. (STIM) and DexCom Inc. (NASDAQ:DXCM) Comparing side by side

Neuronetics Inc. (NASDAQ:STIM) and DexCom Inc. (NASDAQ:DXCM) have been rivals in the Medical Laboratories & Research for quite some time. Below is a review of each business including various aspects such as risk, analyst recommendations, profitability, institutional ownership, dividends, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Neuronetics Inc. 49.25M 6.23 22.88M -1.39 0.00
DexCom Inc. 914.60M 14.48 43.20M 1.69 73.26

In table 1 we can see Neuronetics Inc. and DexCom Inc.’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 provides us Neuronetics Inc. and DexCom Inc.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Neuronetics Inc. -46.46% 0% 0%
DexCom Inc. 4.72% 9.2% 4.4%

Liquidity

The Current Ratio and a Quick Ratio of Neuronetics Inc. are 7.6 and 7.5. Competitively, DexCom Inc. has 4.7 and 4.4 for Current and Quick Ratio. Neuronetics Inc.’s better ability to pay short and long-term obligations than DexCom Inc.

Analyst Ratings

The table shown features the ratings and recommendations for Neuronetics Inc. and DexCom Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Neuronetics Inc. 0 0 0 0.00
DexCom Inc. 0 4 5 2.56

On the other hand, DexCom Inc.’s potential downside is -2.29% and its consensus price target is $145.63.

Institutional & Insider Ownership

Neuronetics Inc. and DexCom Inc. has shares owned by institutional investors as follows: 70.7% and 0%. Insiders owned 1.2% of Neuronetics Inc. shares. Comparatively, insiders own roughly 1.6% of DexCom Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Neuronetics Inc. 11.49% -21.63% -47.02% 0% 0% -28.4%
DexCom Inc. -4.74% -14.66% -14.95% 29.93% 105.85% 115.11%

For the past year Neuronetics Inc. had bearish trend while DexCom Inc. had bullish trend.

Summary

On 11 of the 12 factors DexCom Inc. beats Neuronetics Inc.

Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders. It offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment for adult patients with major depressive disorder. The company's NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed MRI-strength magnetic field, which induces electrical currents designed to stimulate specific areas of the brain associated with mood. Neuronetics, Inc. was incorporated in 2003 and is headquartered in Malvern, Pennsylvania.

DexCom, Inc., a medical device company, together with its subsidiaries, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers in the hospital for the treatment of patients with and without diabetes. Its products include DexCom G4 PLATINUM system for continuous use by adults with diabetes; DexCom G4 PLATINUM with Share, a remote monitoring system; and DexCom G5 Mobile, a CGM system that directly communicates to a patientÂ’s mobile and its data can be integrated with DexCom CLARITY, which is a next generation cloud-based reporting software for personalized, easy-to-understand analysis of trends to improve diabetes management. The company also offers sensor augmented insulin pumps. It has a collaboration and license agreement with Verily Life Sciences LLC to develop a series of next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. The company was founded in 1999 and is headquartered in San Diego, California.